1 Introduction Reactive oxygen species (ROS) have been recognized as key regulators of cancer development and therapeutic response [1]. These molecules arise as metabolic byproducts during cellular processes, mainly within mitochondria through oxidative phosphorylation. Notably, in this regard, NADPH oxidases (NOXs) are also sources of ROS in tumour cells [2, 3].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Amalia Sofianidi
Case Report: Not all signet rings are of gastric origin: a case of lobular breast carcinoma metastatic to the stomach
Abstract Background: Invasive lobular carcinoma (ILC) is a distinct breast cancer subtype with a characteristic infiltrative growth pattern linked to loss of E-cadherin. GI metastases may clinically and histologically mimic primary GI malignancies, creating significant diagnostic pitfalls.
The IGF Signalling Axis in Lung Cancer: Clinical Significance and Therapeutic Challenges
Lung cancer ranks as the leading cause of cancer-related mortality worldwide, with an estimated 1.8 million deaths in 2022 [1]. The medical community has not managed to tame this deadly malignancy so far, which is mainly attributed to its high aggressiveness and our deficient understanding of its distinct biological features. Recently, metabolic reprogramming has emerged as an important cancer hallmark [2], helping us better understand the profile of the tumour.
Targeting the Epigenetic Landscape for Lung Cancer Treatment
The term ‘epigenetics’ was introduced in 1942 by embryologist Conrad Waddington [1]. However, it was not until the early 21st century that the concept began to attract widespread attention. The field reached a pivotal moment in 2022 when Douglas Hanahan identified epigenetic alterations as a fundamental hallmark of cancer, emphasising their critical contribution to tumour development and progression [2].
The Prospects of Curcumin in Non-Small Cell Lung Cancer Therapeutics
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Targeting Epigenetic Alterations Linked to Cancer-Associated Fibroblast Phenotypes in Lung Cancer
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Vistas in Signaling Pathways Implicated in HSV-1 Reactivation
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The Clinical Significance of Cancer-Associated Fibroblasts Classification in Non-Small Cell Lung Cancer
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Leveraging the ROS-TME Axis for Cancer Treatment
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
State of the Art and New Perspectives in Lung Cancer Therapeutics
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Seeing the Future of Lung Cancer Vaccination
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The Promise of Artificial Intelligence in Reshaping Anticancer Drug Development
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Anthocyanins in Non-Small Cell Lung Cancer (NSCLC) Treatment and Prevention
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
YAP/TAZ‐TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma
1 YAP/TAZ BIOLOGY: STRUCTURE/FUNCTION RELATIONSHIPS The yes-associated protein (YAP) and the transcriptional coactivator with PDZ-binding motif (TAZ) are transcriptional cofactors, integral components of the Hippo signalling pathway. In humans, the YAP1 gene is located on chromosome 11q22 and encodes the 65-kDa YAP protein.
Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The Gap of Health Inequalities Amongst Lung Cancer Patients of Different Socioeconomic Status: A Brief Reference to the Greek Reality
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases
Abstract : Simple Summary Takotsubo syndrome (TTS), also known as “broken heart” syndrome, is a rare but serious heart event associated with physical or emotional stress. Patients usually complain about intense chest pain and difficulty in breathing, resembling acute myocardial infarction. Cancer patients are more likely to suffer from TTS and the condition has been linked with the use of several anticancer remedies, such as chemotherapy and targeted therapy.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Amalia
Contact Amalia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack